WallStreetZenWallStreetZen

NASDAQ: ENTO
Entero Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ENTO stock forecasts and price targets.

Forecast return on equity

Is ENTO forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ENTO forecast to generate an efficient return on assets?

Company
-3.14%
Industry
36.52%
ENTO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ENTO earnings per share forecast

What is ENTO's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.77
Avg 3 year Forecast
-$1.68

ENTO revenue forecast

What is ENTO's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ENTO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ENTO$4.46N/AN/A
GLMD$1.35N/AN/A
NBY$1.20N/AN/A
IBO$0.57N/AN/A
CDIO$4.10N/AN/A
View Top Biotech Stocks

Entero Therapeutics Stock Forecast FAQ

What is ENTO's earnings growth forecast for 2025-2027?

(NASDAQ: ENTO) Entero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 40.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 100.43%.

Entero Therapeutics's earnings in 2025 is -$17,093,152.On average, 3 Wall Street analysts forecast ENTO's earnings for 2025 to be -$2,462,927, with the lowest ENTO earnings forecast at -$2,366,341, and the highest ENTO earnings forecast at -$2,535,366. On average, 3 Wall Street analysts forecast ENTO's earnings for 2026 to be -$2,819,403, with the lowest ENTO earnings forecast at -$2,708,838, and the highest ENTO earnings forecast at -$2,902,327.

In 2027, ENTO is forecast to generate -$2,673,572 in earnings, with the lowest earnings forecast at -$2,568,726 and the highest earnings forecast at -$2,752,206.

If you're new to stock investing, here's how to buy Entero Therapeutics stock.

What is ENTO's revenue growth forecast for 2025-2027?

(NASDAQ: ENTO) Entero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 288.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.75%.

Entero Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast ENTO's revenue for 2025 to be $0, with the lowest ENTO revenue forecast at $0, and the highest ENTO revenue forecast at $0. On average, 3 Wall Street analysts forecast ENTO's revenue for 2026 to be $0, with the lowest ENTO revenue forecast at $0, and the highest ENTO revenue forecast at $0.

In 2027, ENTO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ENTO's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: ENTO) forecast ROA is -3.14%, which is lower than the forecast US Biotechnology industry average of 36.52%.

What is ENTO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ENTO) Entero Therapeutics's current Earnings Per Share (EPS) is -$13.26. On average, analysts forecast that ENTO's EPS will be -$1.55 for 2025, with the lowest EPS forecast at -$1.49, and the highest EPS forecast at -$1.60. On average, analysts forecast that ENTO's EPS will be -$1.77 for 2026, with the lowest EPS forecast at -$1.71, and the highest EPS forecast at -$1.83. In 2027, ENTO's EPS is forecast to hit -$1.68 (min: -$1.62, max: -$1.73).

What is ENTO's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: ENTO) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.